Eledon Pharmaceuticals, Inc. financial data

Symbol
ELDN on Nasdaq
Industry
Pharmaceutical Preparations
Location
19800 Macarthur Blvd., Suite 250, Irvine, CA
State of incorporation
DE
Fiscal year end
December 31
Former names
Novus Therapeutics, Inc. (to 12/22/2020), Tokai Pharmaceuticals Inc (to 5/4/2017)
Latest financial report
10-Q - Q3 2024 - Nov 12, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.02K % -17.5%
Debt-to-equity 574 % +881%
Return On Equity -144 % +40.6%
Return On Assets -21.4 % +86%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 59.7M shares +147%
Common Stock, Shares, Outstanding 41.2M shares +74.9%
Entity Public Float 25.6M USD -23.6%
Common Stock, Value, Issued 41K USD +70.8%
Weighted Average Number of Shares Outstanding, Basic 51.9M shares +73.3%
Weighted Average Number of Shares Outstanding, Diluted 55.5M shares +85.1%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 41.1M USD +34.8%
General and Administrative Expense 15.1M USD +23.8%
Operating Income (Loss) -56.2M USD +38.5%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -88M USD -139%
Net Income (Loss) Attributable to Parent -21.7M USD +85%
Earnings Per Share, Basic -1.71 USD/shares +78.4%
Earnings Per Share, Diluted -3.08 USD/shares +61.1%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 6.75M USD +84.1%
Cash, Cash Equivalents, and Short-term Investments 78.2M USD +31.2%
Other Assets, Current 442K USD +391%
Assets, Current 81.5M USD +29.4%
Operating Lease, Right-of-Use Asset 471K USD +2.61%
Goodwill 0 USD
Other Assets, Noncurrent 210K USD -9.87%
Assets 115M USD +19.3%
Accounts Payable, Current 5.86M USD +1160%
Liabilities, Current 12.5M USD +331%
Deferred Income Tax Liabilities, Net 1.75M USD 0%
Operating Lease, Liability, Noncurrent 315K USD +280%
Liabilities 38.5M USD -36.3%
Accumulated Other Comprehensive Income (Loss), Net of Tax 102K USD
Retained Earnings (Accumulated Deficit) -311M USD -7.49%
Stockholders' Equity Attributable to Parent 76.1M USD +114%
Liabilities and Equity 115M USD +19.3%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -8.74M USD +11.9%
Net Cash Provided by (Used in) Investing Activities 9.78M USD
Common Stock, Shares Authorized 200M shares 0%
Common Stock, Shares, Issued 41.2M shares +74.9%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 1.04M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 6.75M USD +84.1%
Deferred Tax Assets, Valuation Allowance 30.8M USD +42.2%
Deferred Tax Assets, Gross 36.8M USD +32.1%
Operating Lease, Liability 501K USD +4.59%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent 77.1M USD
Lessee, Operating Lease, Liability, to be Paid 571K USD +17.2%
Operating Lease, Liability, Current 186K USD -53%
Lessee, Operating Lease, Liability, to be Paid, Year Two 197K USD
Lessee, Operating Lease, Liability, to be Paid, Year One 191K USD -50.8%
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure +282%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 70K USD +775%
Lessee, Operating Lease, Liability, to be Paid, Year Three 100K USD
Deferred Tax Assets, Operating Loss Carryforwards 18.1M USD +18.8%
Preferred Stock, Shares Authorized 5M shares 0%
Unrecognized Tax Benefits 3.64M USD +36.5%
Operating Lease, Payments 102K USD +22.9%
Share-based Payment Arrangement, Expense 8.25M USD +30.8%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%